Klinik Südhang
Kirchlindach, Canton of Bern, CH-3038, Switzerland
NCT Number: NCT02196142
To investigate the effects of cortisol on alcohol craving and stress reactivity in alcohol addicted subjects.
Randomized, double-blind, placebo-controlled, cross-over, single administration of study medication.
Study hypothesis: Cortisol has an inhibiting effect on alcohol craving and stress reactivity in alcohol dependent subjects.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Kirchlindach, Canton of Bern, CH-3038, Switzerland
Background
Alcohol dependence is a chronically and relapsing disorder with major impact on the persons psychological, physiological and social functioning. There is extensive evidence from animal and human studies pointing out the important role of addiction memory in the development and maintenance of the disorder.
Cognitive behavioural therapy (CBT) has proven its high effectiveness in the treatment for addictive disorders. A core element of CBT are exposure techniques that are comparable to extinction and habituation learning. The repeated exposure to alcohol related cues in the absence of alcohol ingestion will lead to extinction of conditioned responses, thus reducing the probability of relapse to alcohol taking behaviour.
Studies have shown that glucocorticoids impair memory retrieval in healthy subjects. In fact, the investigators could show that cortisol has a fear reducing effect in patients with post-traumatic stress disorder and in phobic patients, resulting particularly in reduced symptoms of anxiety and in reduced stress reactivity. Interestingly enough, pharmacologically induced high levels of glucocorticoids lowered the subjective feeling of anxiety and stress in situations activating per se the HPA-axis. Further it has been shown that the combined therapy of glucocorticoid administration and exposition based psychotherapy leads to better therapy outcome in patients with specific phobias.
Objective
The goal of this study is to examine the acute effects of glucocorticoids administration on alcohol craving and stress reactivity of abstinent alcohol dependent patients. On the basis of clinical research in anxiety disorders, the investigators expect that a pharmacologically increased cortisol level may impair the retrieval of addiction memory, which is indicated by less craving during the alcohol exposition, while exposition therapy enhances consolidation of corrective experiences. Similar to the research in anxiety patients, the investigators aim to examine whether cortisol administration could help improve the effects of exposition therapy in patients with alcohol dependence. The purpose is to decrease therapy duration through cortisol administration in addition to already well proven therapies and make the therapy more efficient as well as a factor in reducing healthcare costs.
Methods
Patients undergo two identical experimental sessions between the 6th and 8th week (one week in between) of their 12-week inpatient treatment program for alcohol dependence. The experiment takes place in the experimental rooms of the clinic Südhang between 1 and 6 pm. One hour before the confrontation with alcohol associated stimuli patients receive either 20mg of hydrocortisone or placebo (oral administration). The experiment consists of a computer based picture task (alcoholic and neutral pictures) and an in-vivo exposure task. Psychological (craving, stress, arousal) and physiological (heart rate, saliva cortisol) parameters are repeatedly measured over the course of the experiment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drug: Cortisol 20mg
Drug: Placebo Mannitol
Time frame: During and after presentation of drug stimuli, expected to be after 10 minutes
Measured by Alcohol Urge Questionnaire & Visual Analogue Scale
Time frame: After presentation of drug stimuli, expected to be after 20 minutes
Time frame: During and after presentation of drug stimuli, expected to be after 10 minutes
Time frame: After presentation of drug stimuli, expected to be after 90 minutes
Insel Gruppe AG, University Hospital Bern
Other
Acronym: CAR-Bern 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05606900
Alcohol Craving, Alcohol Use Disorder
Izmir, Turkey (Türkiye)
View Trial DetailsNCT02075424
Behavior, Behavioral Symptoms
Metz, France
View Trial DetailsNCT04900675
Behavior, Behavioral Symptoms
Innsbruck, Tyrol, Austria
View Trial DetailsNCT05506644
Anxiety, Anxiety Disorders
San Diego, California, United States
View Trial Details